RTW Investments (RTW) is a global, full life-cycle investment firm and company builder that focuses on identifying transformational and disruptive innovations across the biopharmaceutical and medical technologies sectors. As a leading partner of industry and academia, RTW combines deep scientific expertise with a solution-oriented investment approach to support emerging medical therapies and the companies and/or academics developing them.
RTW founded JIXING in 2019 and has been supporting the company with an excellent incubation team. RTW previously incubated Rocket Pharmaceuticals (NASDAQ: RCKT), which focuses on developing first-in-class gene therapies for rare and devastating, inherited genetic diseases.
For further information please visit www.RTWfunds.com.
Cytokinetics (Nasdaq: CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and best-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. Cytokinetics scientists have discovered a robust pipeline of small molecule muscle activators and inhibitors; omecamtiv mecarbil, a cardiac myosin activator; reldesemtiv, a fast skeletal muscle troponin activator (FSTA); aficamten (CK-274) and CK-271, cardiac myosin inhibitors; CK-136, a cardiac troponin activator; and CK-601, a next-generation FSTA.
For further information please visit www.cytokinetics.com
Milestone Pharmaceuticals (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone’s lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation and rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States.
For further information please visit www.milestonepharma.com
Oyster Point Pharma (Nasdaq: OYST) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Oyster Point Pharma’s lead clinical program is focused on the development of Tyrvaya (varenicline), previously called OC-01, nasal spray, a highly selective cholinergic agonist, being developed as a preservative-free nasal spray to treat the signs and symptoms of dry eye disease and neurotrophic keratopathy. In October 2021, Oyster Point announced NDA approval of Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease.
For further information please visit https://oysterpointrx.com/